Patients who received anthracyclines in addition to taxane-based chemotherapy experienced improved survival. Patients with a higher recurrence score more likely benefited from anthracyclines.

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...

CardioOncology, shows that administration of the SGLT2 inhibitor empagliflozin to pigs receiving anthracyclines preserves ...

"Anthracyclines should be considered in patients with high genomic-risk, hormone receptor-positive [HR+], node-negative disease," she concluded. The study added to an ongoing debate about the role ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

As their use increased, however, it became evident that anthracyclines carry a risk of cardiotoxicity, which in some cases could be irreversible, as well as a risk of secondary leukemia.

Some cytotoxic anticancer drugs may boost an immunogenic molecular signal of apoptosis. Why did anthracyclines have this property, whereas many other chemotherapeutic agents did not? It appears ...

Patients with no exposure to anthracyclines served as the reference group. Magnitude of risk is expressed as odds ratio, which was obtained using conditional logistic regression adjusting for age at ...

A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...

A non-exhaustive list of examples of drugs that combine anticancer and immunostimulatory effects includes: imatinib mesylate, cyclophosphamide, anthracyclines and 5-fluorouracil. Imatinib mesylate ...